Theratechnologies (THTX) “announced that it has resumed distribution of EGRIFTA SV, following correspondence from the U.S. Food and Drug Administration that allows the Company to release two recently manufactured batches of EGRIFTA SV. The product is ready for immediate shipment to network pharmacies. Review of the Company’s Prior Approval Supplement by the FDA is ongoing with an action goal date of April 18, 2025. EGRIFTA SV is distributed in the United States only.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies expects Egrifta SV shortage this month
- Impending Shortage of Theratechnologies’ EGRIFTA SV® Amid Manufacturing Shutdown
- Theratechnologies Seeks FDA Approval for Manufacturing Changes to EGRIFTA SV®
- Theratechnologies Seeks FDA Approval for EGRIFTA SV® Changes
- Theratechnologies announces filing of PAS with FDA for manufacturing environment